BidaskClub lowered shares of LeMaitre Vascular (NASDAQ:LMAT) from a hold rating to a sell rating in a report released on Tuesday morning, BidAskClub reports.

Several other research analysts have also recently weighed in on LMAT. Lake Street Capital upgraded shares of LeMaitre Vascular from a hold rating to a buy rating and set a $40.00 price target for the company in a report on Thursday, October 24th. Zacks Investment Research upgraded shares of LeMaitre Vascular from a hold rating to a buy rating and set a $33.00 price target for the company in a report on Tuesday. Barrington Research reiterated a buy rating and issued a $38.00 price target on shares of LeMaitre Vascular in a report on Friday, February 7th. ValuEngine cut shares of LeMaitre Vascular from a hold rating to a sell rating in a report on Friday, February 7th. Finally, First Analysis cut shares of LeMaitre Vascular from a strong-buy rating to an outperform rating and upped their price target for the company from $37.00 to $40.00 in a report on Thursday, October 24th. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating and three have given a buy rating to the company’s stock. LeMaitre Vascular has an average rating of Hold and an average target price of $37.75.

Shares of LeMaitre Vascular stock traded up $0.27 on Tuesday, hitting $30.11. The company had a trading volume of 75,439 shares, compared to its average volume of 139,486. The firm has a market capitalization of $569.65 million, a P/E ratio of 34.22, a P/E/G ratio of 3.63 and a beta of 1.23. LeMaitre Vascular has a twelve month low of $24.71 and a twelve month high of $38.64. The stock has a 50-day moving average of $35.56 and a 200-day moving average of $34.15.

LeMaitre Vascular (NASDAQ:LMAT) last released its quarterly earnings results on Thursday, February 6th. The medical instruments supplier reported $0.23 earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.23. The company had revenue of $30.20 million during the quarter, compared to analysts’ expectations of $30.44 million. LeMaitre Vascular had a net margin of 15.30% and a return on equity of 12.85%. The business’s quarterly revenue was up 6.3% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.30 earnings per share. As a group, equities analysts predict that LeMaitre Vascular will post 0.94 EPS for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Thursday, March 19th. Stockholders of record on Tuesday, March 3rd will be issued a $0.095 dividend. This represents a $0.38 annualized dividend and a dividend yield of 1.26%. The ex-dividend date is Monday, March 2nd. This is a boost from LeMaitre Vascular’s previous quarterly dividend of $0.09. LeMaitre Vascular’s dividend payout ratio is 38.64%.

In related news, CFO Joseph P. Pellegrino, Jr. sold 11,182 shares of the stock in a transaction on Wednesday, November 20th. The shares were sold at an average price of $35.01, for a total transaction of $391,481.82. Following the completion of the transaction, the chief financial officer now owns 184,054 shares in the company, valued at $6,443,730.54. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Joseph P. Pellegrino, Jr. sold 121,159 shares of the stock in a transaction on Thursday, December 5th. The stock was sold at an average price of $34.93, for a total transaction of $4,232,083.87. Insiders have sold 332,239 shares of company stock valued at $11,824,710 in the last 90 days. 19.60% of the stock is currently owned by corporate insiders.

A number of institutional investors and hedge funds have recently made changes to their positions in LMAT. Principal Financial Group Inc. boosted its holdings in LeMaitre Vascular by 297.4% during the fourth quarter. Principal Financial Group Inc. now owns 533,334 shares of the medical instruments supplier’s stock worth $19,174,000 after purchasing an additional 399,120 shares during the last quarter. Russell Investments Group Ltd. boosted its holdings in LeMaitre Vascular by 92.3% during the third quarter. Russell Investments Group Ltd. now owns 360,859 shares of the medical instruments supplier’s stock worth $12,333,000 after purchasing an additional 173,214 shares during the last quarter. Copeland Capital Management LLC boosted its holdings in LeMaitre Vascular by 38.7% during the third quarter. Copeland Capital Management LLC now owns 536,199 shares of the medical instruments supplier’s stock worth $18,327,000 after purchasing an additional 149,642 shares during the last quarter. Morgan Stanley boosted its holdings in LeMaitre Vascular by 151.7% during the second quarter. Morgan Stanley now owns 202,672 shares of the medical instruments supplier’s stock worth $5,671,000 after purchasing an additional 122,152 shares during the last quarter. Finally, Foundry Partners LLC acquired a new position in LeMaitre Vascular during the fourth quarter worth $4,217,000. Institutional investors and hedge funds own 79.54% of the company’s stock.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide. The company offers angioscope, a fiber optic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries or veins; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to temporarily perfuse the blood and other fluids into the vasculature.

See Also: Outstanding Shares, Buying and Selling Stocks

Receive News & Ratings for LeMaitre Vascular Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular and related companies with MarketBeat.com's FREE daily email newsletter.